Professor Tells UN, Governments Of Coming “Tsunami” Of Data And Artificial Intelligence 21/02/2018 by William New, Intellectual Property Watch 1 Comment NEW YORK — Technology is moving so fast it could cause harm to humans even as it brings remarkable advances unless governments act, an Israeli professor and visionary thinker told a gathering of government and United Nations representatives here last week. A hint? In the next five years we are all going to be cyborgs. In fact most of us already are.
WHO Names High-Profile Commission On Non-Communicable Diseases 16/02/2018 by William New, Intellectual Property Watch 1 Comment The World Health Organization today announced a new high-level commission of heads of state, ministers and other leaders in health and development to come up with “bold and innovative solutions” against non-communicable diseases such as heart and respiratory diseases, cancers and diabetes. The chairs of the commission include the presidents of Uruguay, Sri Lanka, and Finland, the Russian health minister, and a former minister of Pakistan who was a candidate for director general of the WHO. They are joined by nearly two dozen others, including corporate public figures Michael Bloomberg and Jack Ma.
Interview With Peter Vanderheyden, CEO Of Article One Partners 15/02/2018 by Intellectual Property Watch, Intellectual Property Watch Leave a Comment Article One Partners (AOP), the world leader in crowdsourced intellectual property research, is now into their 10th year. Intellectual Property Watch recently arranged an interview with Article One Partners CEO Peter Vanderheyden to get an update on how the company has evolved in response to the ever-changing IP landscape, and in light of their commitment to IP quality.
Innovations For All: Swiss-Led Panel Looks At What Works, What Doesn’t 14/02/2018 by William New, Intellectual Property Watch Leave a Comment The current innovation system has yielded many important innovations and extended human life, nobody disputes this. But what about the cases where it hasn’t and a problem persists? A panel of health experts organised recently by the Swiss government and including representatives of the pharmaceutical industry, the World Health Organization, academia, and a research institution held an unusually open and positive discussion that sought to get underneath the issue.
Do We Need A Global Body To Set Priorities For Diseases And Research? 14/02/2018 by William New and Catherine Saez, Intellectual Property Watch Leave a Comment A recent panel of health experts gathered at the hallowed Swiss Intellectual Property Institute in Bern (which counts Albert Einstein among its alumni) tackled some of the toughest questions facing global health policymakers with an eye toward actually solving them and not just restating polarised positions. One of the ideas discussed at the event was how priorities for diseases and research are handled at the global level.
Trump Budget Would Slash Funding For Health, International Organisations 13/02/2018 by William New, Intellectual Property Watch 1 Comment The Trump administration this week proposed drastic cuts in funding for international activities including foreign policy and global health in 2019, while further building up military and big business activities. Programs related to international activities will have to prove their value to American interests and other countries are demanded to pay more, according to the proposed budget sent yesterday to Congress, which is ultimately expected to set about the task of restoring numerous programs.
Leadership And Change: An Interview With Medicines Patent Pool Board Chair Marie-Paule Kieny 08/02/2018 by Catherine Saez, Intellectual Property Watch Leave a Comment The unexpected announcement in December of the resignation of the Medicines Patent Pool executive director left the Pool searching for its new head. Marie-Paule Kieny, former World Health Organization assistant director general, now chair of the MPP governance board stepped in to oversee the MPP while the search goes on. She sat down recently for an interview with Intellectual Property Watch to explain that MPP is conducting business as usual, and is keeping firm in its plan to release the results of a feasibility study analysing the possibility for MPP to extend its licensing activities to other essential medicines still under patent.
A Brief Sketch Of Privilegio In The Venetian Renaissance 07/02/2018 by Intellectual Property Watch 2 Comments Gavin Keeney writes: As a type of historical morality tale, especially given arguments currently before the European Commission regarding copyright reform and “neighboring rights,” this short treatise addresses the origins of copyright in the Venetian Renaissance in the late 1400s under the aegis of privilegio, notably first granted to authors (author-publishers) versus printers (printer-publishers). Subsequently, printers as publishers would command the lion’s share of such rights to works. Arguably, Venetian privilege transferred the immemorial aspect of written works (here considered “moral rights” for works) to authors in a casual, yet emphatic manner leading to modern copyright. With contemporary copyright nominally belonging to authors, but in fact belonging by expropriation to presses and platforms, it is likely that one of the few solutions, short of benevolent presses fully sharing rights with authors, is for moral rights to return to works by way of the author renouncing copyright but refusing the arrogation of such renounced rights to presses and platforms.
Leaked Letter Shows Pressure On Colombia Not To Issue Compulsory Licence For Glivec 06/02/2018 by William New, Intellectual Property Watch 1 Comment A newly leaked 2016 letter from the CEO of Novartis to the president of Colombia, made available by Swiss group Public Eye, shows the level of concern the Swiss pharmaceutical company had over the effect of possible issuance of a compulsory licence for Novartis drug Glivec in the pivotal South American economy.
Medicines Innovation And Access: Swiss Stimulate New Thinking 06/02/2018 by Catherine Saez, Intellectual Property Watch Leave a Comment BERN, Switzerland — What if reaching the United Nations Sustainable Development Goals on access to health for all depended on the willingness of all actors to see beyond outdated dichotomies? The concept may seem obvious, but is easier described than done. In an effort to break silos, the Swiss Federal Institute of Intellectual Property (IPI) brought together stakeholders of all sides last week to discuss how to harness political and economic will to achieve innovation leading to new medicines that are available and affordable for all in need.